HSBC Holdings’s Novavax NVAX Stock Holding History

HSBC Holdings’s Portfolio NVAX Stock Details NVAX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-1,000,000	Closed	-$147M	–	3415
2021 Q4	$147M	Buy	+1,000,000	New	+$172M	0.14%	127

Other funds holding NVAX

SCM

Shah Capital Management Raleigh, North Carolina $605M AUM 43.69% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Sanofi Paris, France $534M AUM 205.96% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Coatue Management New York $48.6B AUM 94.27% 1-Year Est. Return

HSBC Holdings's NVAX Position: Q2 2026 in Review

HSBC Holdings increased its Novavax (NVAX) stake by 136% in Q2 2026, buying an estimated $227K and bringing the position to 43,966 shares worth $415K. The position accounts for ﹤0.01% of the portfolio, ranked #2370.

HSBC Holdings first reported a position in NVAX in Q4 2014 and has held it in 28 quarters since. The position peaked at $148M in Q4 2021. 268 funds tracked by Wall St. Rank hold NVAX as of Q2 2026.

HSBC Holdings held 43,966 shares of Novavax worth $415K as of Q2 2026.
HSBC Holdings bought 25,338 Novavax shares in Q2 2026, an estimated $227K.
Novavax made up ﹤0.01% of HSBC Holdings's portfolio in Q2 2026, its #2370 holding.
HSBC Holdings first reported a position in Novavax in Q4 2014 and has held it in 28 quarters since.
HSBC Holdings's Novavax position peaked at $148M in Q4 2021.
268 funds tracked by Wall St. Rank held Novavax as of Q2 2026.

Based on HSBC Holdings's 13F filing for Q2 2026, filed 14 Aug 2026.